Article Versions Notes

Suzuki K, Gunji T, Kawashima M, Uryu H, Nagao R, Saito T, Nishiwaki K, Yano S. Relative Dose Intensity of Daratumumab, Lenalidomide, and Dexamethasone in Multiple Myeloma. Cancers. 2025; 17(3):470. https://doi.org/10.3390/cancers17030470

Suzuki, Kazuhito, Tadahiro Gunji, Masaharu Kawashima, Hideki Uryu, Riku Nagao, Takeshi Saito, Kaichi Nishiwaki, and Shingo Yano. 2025. "Relative Dose Intensity of Daratumumab, Lenalidomide, and Dexamethasone in Multiple Myeloma" Cancers 17, no. 3: 470. https://doi.org/10.3390/cancers17030470

Suzuki, K., Gunji, T., Kawashima, M., Uryu, H., Nagao, R., Saito, T., Nishiwaki, K., & Yano, S. (2025). Relative Dose Intensity of Daratumumab, Lenalidomide, and Dexamethasone in Multiple Myeloma. Cancers, 17(3), 470. https://doi.org/10.3390/cancers17030470